The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine

Cimetidine is known to cause drug-drug interactions (DDIs) with organic cations in the kidney, and a previous clinical study showed that coadministration of cimetidine or probenecid with fexofenadine (FEX) decreased its renal clearance. FEX was taken up into human kidney by human organic anion transporter (hOAT) 3 (SLC22A8), but the mechanism of its luminal efflux has not been clarified. The present study examined the molecular mechanism of these DDIs. Saturable uptake of FEX was observed in human kidney slices, with Km and Vmax values of 157 ± 7 μM and 418 ± 16 nmol/15 min/g kidney, respectively. Cimetidine only slightly inhibited its uptake even at 100 μM, far greater than its clinically relevant concentration, whereas 10 μM probenecid markedly inhibited its uptake. As candidate transporters for the luminal efflux of FEX, we focused on human multidrug and toxin extrusions MATE1 (SLC47A1) and MATE2-K (SLC47A2). Saturable uptake of FEX could be observed in human embryonic kidney 293 cells expressing human MATE1 (hMATE1), whereas hMATE2-K-specific uptake of FEX was too small to conduct its further kinetic analysis. The hMATE1-mediated uptake clearance of FEX was inhibited by cimetidine in a concentration-dependent manner, and it was decreased to 60% of the control value in the presence of 3 μM cimetidine. Taken together, our results suggest that the DDI of FEX with probenecid can be explained by the inhibition of renal uptake mediated by hOAT3, whereas the DDI with cimetidine is mainly caused by the inhibition of hMATE1-mediated efflux of FEX rather than the inhibition of its renal uptake process.

[1]  K. Inui,et al.  Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. , 2007, American journal of physiology. Renal physiology.

[2]  A. Somogyi,et al.  Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.

[3]  Christel A. S. Bergström,et al.  Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). , 2008, Journal of medicinal chemistry.

[4]  M. Eve,et al.  Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. , 2000, British journal of clinical pharmacology.

[5]  H. Kasanuki,et al.  Effect of cimetidine and probenecid on pilsicainide renal clearance in humans , 2000, Clinical pharmacology and therapeutics.

[6]  N. Yasui-Furukori,et al.  Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[7]  M. Okuda,et al.  Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). , 2004, European journal of pharmacology.

[8]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[9]  H. Kusuhara,et al.  P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION , 2005, Drug Metabolism and Disposition.

[10]  B. Feng,et al.  Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.

[11]  S. Masuda,et al.  Molecular Cloning, Functional Characterization and Tissue Distribution of Rat H+/Organic Cation Antiporter MATE1 , 2006, Pharmaceutical Research.

[12]  A. Enomoto,et al.  Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. , 2004, Journal of pharmacological sciences.

[13]  Katsuhisa Inoue,et al.  Molecular Identification and Functional Characterization of Rat Multidrug and Toxin Extrusion Type Transporter 1 as an Organic Cation/H+ Antiporter in the Kidney , 2006, Drug Metabolism and Disposition.

[14]  Thomas J. Raub,et al.  Multidrug Resistance-Associated Protein 2 Is Primarily Responsible for the Biliary Excretion of Fexofenadine in Mice , 2007, Drug Metabolism and Disposition.

[15]  A. Somogyi,et al.  Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs , 2004, European Journal of Clinical Pharmacology.

[16]  K. Maeda,et al.  Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine , 2008, Molecular Pharmacology.

[17]  Yuichi Sugiyama,et al.  Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.

[18]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[19]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[20]  A. Somogyi,et al.  Stereoselective inhibition of pindolol renal clearance by cimetidine in humans , 1992, Clinical pharmacology and therapeutics.

[21]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[22]  H. Kusuhara,et al.  Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.

[23]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Jörg Huwyler,et al.  Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.

[25]  A. Somogyi,et al.  Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. , 1986, The Journal of pharmacology and experimental therapeutics.

[26]  T. Komatsu,et al.  Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. , 2006, American journal of physiology. Cell physiology.

[27]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Maeda,et al.  INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID , 2006, Drug Metabolism and Disposition.

[29]  Katsuhisa Inoue,et al.  Functional Characterization of Multidrug and Toxin Extrusion Protein 1 as a Facilitative Transporter for Fluoroquinolones , 2009, Journal of Pharmacology and Experimental Therapeutics.

[30]  Kazuya Maeda,et al.  Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans , 2008, Drug Metabolism and Disposition.